naphtho[1,2-b]furan-2-methanol | 103997-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: naphtho[1,2-b]furan-2-methanol
• 英文别名: benzo[g][1]benzofuran-2-ylmethanol
• CAS: 103997-04-2
• 化学式: C₁₃H₁₀O₂
• 分子量: 198.221
• InChiKey: RZEYBGDFXAXZJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  naphtho[1,2-b]furan-2-methanol 以84%的产率得到
  参考文献：
  名称：

  BAIR, KENNETH W.

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl naphthol<1,2-b>furan-2-carboxylate 、 锂硼氢 生成 naphtho[1,2-b]furan-2-methanol
  参考文献：
  名称：

  BAIR, KENNETH W.

  摘要：

  DOI：

文献信息

• Certain substituted naphthofurans with anti-tumor properties
  申请人：Burroughs Wellcome Co.

  公开号：US05008286A1

  公开（公告）日：1991-04-16

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acide addition salts thereof; wherein Ar is a fused tricyclic aromatic ring system containing a maximum of 14 ring atoms and at least one heteroatom or a fused pentacyclic ring system with at least 4 aromatic rings containing a maximum of 22 ring atoms and at least one heteroatom; or a substituted derivative thereof; for either the tricyclic or pentacyclic ring system there is a maximum of one heteroatom for each ring present but preferably only one or two of the rings contain a heteroatom; the rings forming the tricyclic or the pentacyclic ring system contain five or six atoms; the heteroatoms are conveniently nitrogen, phosphorus, oxygen, sulfur or selenium; suitably the heteroatom is oxygen, sulfur or nitrogen; the tricyclic or the pentacyclic ring system should be planar or deviate only slightly from planarity; suitably the ring system is aromatic or contains one non-aromatic ring; preferably the ring system is aromatic; nitrogen atoms contained in five-membered rings are substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl. The compounds have biocidal properties.

  本发明涉及化合物的公式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，总共不超过29个碳原子）；醚，酯；酸盐；其中Ar是含有最多14个环原子和至少一个杂原子的融合三环芳香环系统或至少4个芳香环的含有最多22个环原子和至少一个杂原子的融合五环系统；或其取代衍生物；对于三环或五环系统，每个环最多有一个杂原子，但最好只有一个或两个环含有杂原子；形成三环或五环系统的环包含五个或六个原子；杂原子方便地是氮、磷、氧、硫或硒；适宜的杂原子是氧、硫或氮；三环或五环系统应该是平面的或仅略微偏离平面；合适的环系统是芳香的或包含一个非芳香环；最好环系统是芳香的；五元环中含氮原子被氢、甲基或乙基取代；R.sup.1含有不超过八个碳原子，是一个基团##STR1##其中m为0或1；R.sup.5是氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-5烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10是氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14是氢、甲基、羟基或羟甲基。这些化合物具有杀生物性能。
• Dibenzothiphene and naphthalenethiophene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04965285A1

  公开（公告）日：1990-10-23

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tricyclic aromatic ring system containing a maximum of 14 ring atoms and at least one heteroatom or a fused pentacyclic ring system with at least 4 aromatic rings containing a maximum of 22 ring atoms and at least one heteroatom; or a substituted derivative thereof; for either the tricyclic or pentacyclic ring system there is a maximum of one heteroatom for each ring present but preferably only one or two of the rings contain a heteroatom; the rings forming the tricyclic or the pentacyclic ring system contain five or six atoms; the heteroatoms are conveniently nitrogen, phosphorus, oxygen, sulfur or selenium; suitably the heteroatom is oxygen, sulfur or nitrogen; the tricyclic or the pentacyclic ring system should be planar or deviate only slightly from planarity; suitably the ring system is aromatic or contains one non-aromatic ring; preferably the ring system is aromatic; nitrogen atoms contained in five-membered rings are substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式（I）ArCH.sub.2R.sup.1（I）的化合物或其单甲基或单乙基醚（式（I）的化合物包括这些醚，在总共不超过29个碳原子的情况下）；它们的醚，酯；酸加成盐；其中Ar是一个融合的三环芳香环系统，最多包含14个环原子和至少一个杂原子，或者是一个融合的五环芳香环系统，至少有4个芳香环，最多包含22个环原子和至少一个杂原子；或其取代衍生物；对于三环或五环环系统，每个存在的环中最多只有一个杂原子，但最好只有一个或两个环含有杂原子；形成三环或五环环系统的环包含五个或六个原子；杂原子方便地是氮、磷、氧、硫或硒；适当的杂原子是氧、硫或氮；三环或五环环系统应是平面的或仅略微偏离平面；适当的环系统是芳香的或含有一个非芳香环；最好的环系统是芳香的；五元环中含有的氮原子被氢、甲基或乙基取代；R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1；R.sup.5是氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-5烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10是氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14是氢、甲基、羟基或羟甲基。
• Carbazole derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04970227A1

  公开（公告）日：1990-11-13

  A compound of the formula (I): ArCH.sub.2 R.sup.1 where Ar is ##STR1## where Z is NH, NCH.sub.3 or NEt and R.sup.1 is an hydroxyalkylamino group and pharmaceutically acceptable salts thereof. The compounds are useful as antitumor agents.

  化合物的式子为（I）：ArCH.sub.2R.sup.1，其中Ar是##STR1##其中Z为NH，NCH.sub.3或NEt，R.sup.1为羟基烷基氨基团及其药学上可接受的盐。这些化合物可用作抗肿瘤剂。
• Tricyclic derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US05017600A1

  公开（公告）日：1991-05-21

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tricyclic aromatic ring system containing a maximum of 14 ring atoms and at least one heteroatom or a fused pentacyclic ring system with at least 4 aromatic rings containing a maximum of 22 ring atoms and at least one heteroatom; or a substituted derivative thereof; for either the tricyclic or pentacyclic ring system there is a maximum of one heteroatom for each ring present but preferably only one or two of the rings contain a heteroatom; the rings forming the tricyclic or the pentacyclic ring system contain five or six atoms; the heteroatoms are conveniently nitrogen, phosphorus, oxygen, sulfur or selenium; suitably the heteroatom is oxygen, sulfur or nitrogen; the tricyclic or the pentacyclic ring system should be planar or deviate only slightly from planarity; suitably the ring system is aromatic or contains one non-aromatic ring; preferably the ring system is aromatic; nitrogen atoms contained in five-membered rings are substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式(I) ArCH.sub.2 R.sup.1 (I)或其单甲基或单乙基醚（公式(I)的化合物包括这些醚，总碳原子数不超过29个）；其醚，酯；酸加成盐；其中Ar是一个融合的三环芳香环系统，包含最多14个环原子和至少一个杂原子，或者是至少4个芳香环的融合五环环系统，包含最多22个环原子和至少一个杂原子；或者是其取代衍生物；对于三环或五环环系统，每个环中最多有一个杂原子，但最好只有一个或两个环含有杂原子；形成三环或五环环系统的环包含五个或六个原子；杂原子方便地是氮、磷、氧、硫或硒；适当的杂原子是氧、硫或氮；三环或五环环系统应是平面的或仅略微偏离平面；适当的环系统是芳香的或含有一个非芳香环；最好是芳香的；五元环中含有的氮原子被氢、甲基或乙基取代；R.sup.1不含有超过八个碳原子，是一个组##STR1##其中m为0或1；R.sup.5是氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-5烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10是氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14是氢、甲基、羟基或羟甲基。
• Dibenzofurans having anti-tumor activity
  申请人：Burroughs Wellcome Co.

  公开号：US05049581A1

  公开（公告）日：1991-09-17

  The present invention relates to compounds of formula (I) ArCh.sub.2 R or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tricyclic aromatic ring system containing a maximum of 14 ring atoms and at least one heteroatom or a fused pentacyclic ring system with at least 4 aromatic rings containing a maximum of 22 ring atoms and at least one heteroatom; or a substituted derivative thereof; for either the tricyclic or pentacyclic ring system there is a maximum of one heteroatom for each ring present but preferably only one or two of the rings contain a heteroatom; the rings forming the tricyclic or the pentacyclic ring system contain five or six atoms; the heteroatoms are conveniently nitrogen, phosphorus, oxygen, sulfur or selenium; suitably the heteroatom is oxygen, sulfur or nitrogen; the tricyclic or the pentacyclic ring system should be planar or deviate only slightly from planarity; suitably the ring system is aromatic or contains one non-aromatic ring; preferably the ring system is aromatic; nitrogen atoms contained in five-membered rings are substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; --C--C-- is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCh.sub.2 R或其单甲基或单乙基醚（包括这些醚的公式（I）化合物总共不超过29个碳原子）；其醚，酯；酸盐；其中Ar是融合的三环芳香环系统，包含最多14个环原子和至少一个杂原子，或者是至少4个芳香环的融合五环芳香环系统，其中包含最多22个环原子和至少一个杂原子；或其取代衍生物；对于三环或五环芳香环系统，每个存在的环中最多有一个杂原子，但最好只有一个或两个环含有杂原子；形成三环或五环芳香环系统的环包含五个或六个原子；杂原子方便地是氮、磷、氧、硫或硒；适宜的杂原子是氧、硫或氮；三环或五环芳香环系统应该是平面的或者只略微偏离平面；适宜的环系统是芳香的或者包含一个非芳香环；最好的情况是环系统是芳香的；五元环中含有的氮原子被氢、甲基或乙基取代；R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-5烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；--C--C--是一个五元或六元饱和碳环；R.sup.10为氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14为氢、甲基、羟基或羟甲基。